KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases

Journal of Clinical Oncology

Volumn 27, Issue 1, 2009, Pages 158-159

  Velho, Sérgia ^a   Oliveira, Carla ^b   Seruca, Raquel ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MOLECULAR MARKER; MUTANT PROTEIN; PANITUMUMAB; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; LETTER; LYMPH NODE METASTASIS; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; WILD TYPE;

COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; LYMPHATIC METASTASIS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 58149327464     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1525     Document Type: Letter

References (14)

1. Artale S, Sartore-Bianchi A, Veronese S, et al: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:4217-4219, 2008
2. Jonker D, O'Callaghan C, Karapetis C, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
3. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
4. Ng K, Zhu A: Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol 65:8-20, 2008
5. Raponi M, Winkler H, Dracopoli N: KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 8:413-418, 2008
6. Lièvre A, Bachet J, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
7. Lièvre A, Bachet J, Corre DL, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
8. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96:1166-1169, 2007
9. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008
10. Amado R, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
11. Benvenuti S, Sartore-Bianchi A, Nicolantonio FD, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007
12. Freeman D, Juan T, Reiner M, et al: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7:184-190, 2008
13. de Reyniès A, Boige V, Milano G, et al: KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 26:2228-2230, 2008
14. Oliveira C, Velho S, Moutinho C, et al: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26:158-163, 2007